Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Impressive annual returns suggest the company's improved performance. Its focus on revenue growth proves strategic, although further profitability analysis is wise given the substantial share appreciation.
Gapping up $コインベース(COIN.US)$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.) $マイクロストラテジー(MSTR.US)$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
miStaMac :
I had put in a order for 104 shares of UiPath. I saw the same comment of Cathy Woods selling Nvidia and buying UiPath. I cancelled order ASAP. UiPath down,$19.30. "Badlucksleptrock".
Exact Sciences Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum $イグザクド・サイエンシズ(EXAS.US)$Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum. Baird Upgrades Alcon to Outperform, Raises Price Target to $90 Baird analyst Jeff Johnson upgrades$アルコン(ALC.US)$from Neutral to Outperform and raises the price target from $75 to $90. BofA Securities Upgrades Celsius Holdings to Buy, Raises Price Target to $125 B o...
イグザクド・サイエンシズに関するコメント
One of the best AI stocks. Still trading at the best price.
コラムToday's Pre-Market Stock Movers: FDX, COIN, RIVN, EXAS, and More
$コインベース(COIN.US)$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.)
$マイクロストラテジー(MSTR.US)$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
She’s the anti Peter Lynch
"SELLING YOUR WINNERS AND HOLDING YOUR LOSERS IS LIKE
CUTTING THE FLOWERS AND WATERING THE WEEDS."
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2023 Update
ARK Invest’s 13F portfolio value increased from $11.54B to $14.55B this quarter.
They increased Tesla, Coinbase Global, Block, Unity Software, and Ginkgo Bioworks while decreasing Exact Sciences, Twilio, and NVIDIA during the quarter.
The top three positions are Tesla, Roku, and Zoom Video, and they add up to ~...
コラムUS Top Rating Updates on 5/10: PYPL, EXAS, CELH, GTLB and More
$イグザクド・サイエンシズ(EXAS.US)$ Price Target Raised to $85.00/Share From $55.00 by Craig-Hallum.
Baird Upgrades Alcon to Outperform, Raises Price Target to $90
Baird analyst Jeff Johnson upgrades $アルコン(ALC.US)$ from Neutral to Outperform and raises the price target from $75 to $90.
BofA Securities Upgrades Celsius Holdings to Buy, Raises Price Target to $125
B o...
まだコメントはありません